Visible Genetics
This article was originally published in The Gray Sheet
Executive Summary
Investment of $30 mil. by private equity investment firm E.M Warburg, Pincus & Co. is outlined in a letter of intent agreement. The maker of high-performance, automated DNA sequencing systems and kits for the analysis of genes linked to disease plans to use the proceeds to continue development and commercialization of its HIV, hepatitis B and C, and tuberculosis GeneKit products as well as for debt repayment. Second-quarter revenues are estimated at $1.9 mil